[1] |
国家药典委员会. 中华人民共和国药典—一部[M]. 北京:中国医药科技出版社,2015.
|
[2] |
林红强,杨娜,王涵,等. 黄芪的化学成分、药理活性及临床应用研究进展[J]. 世界最新医学信息文摘,2018,18(38):45-47.
|
[3] |
臧凯,张萍,袁彩彩,等. 黄芪多糖提取、纯化及其应用研究进展[J]. 应用化工,2019,48(10):2417-2421.
|
[4] |
黄鑫,廖欢,栾庆祥,等. 黄芪中黄芪多糖的提取分离及应用研究进展[J]. 畜禽业,2019,30(7):8-9.
|
[5] |
唐雨薇,张宇,王宇亮,等. 黄芪多糖分离与结构特征分析[J]. 时珍国医国药,2014,25(5):1097-1100.
|
[6] |
马秀,刘少静,张婉莹,等. 黄芪多糖的分离纯化及药理作用研究进展[J]. 化学工程师,2019,33(8):50-53.
|
[7] |
盛耀光,刘少静,马秀,等. 黄芪多糖的药理作用及剂型研究进展[J]. 广州化工,2019,47(15):28-30.
|
[8] |
黄文静,孙晓春,周瑞,等. 响应面法优化黄芪茎叶总黄酮提取工艺及其抗炎活性研究[J]. 中国现代中药,2018,20(7):871-877.
|
[9] |
袁惠君,李欣,贾鸿震,等. 响应面法优化黄芪总黄酮提取工艺及初步纯化[J]. 草业科学,2019,36(6):1683-1691.
|
[10] |
刘洋,杜婧,沈颜红. 10种药用黄芪属植物化学成分及药理作用的研究进展[J]. 中国实验方剂学杂志,2017,23(18):222-234.
|
[11] |
聂娟,谢丽华,马港圆,等. 中药黄芪的化学成分及药理作用研究进展[J]. 湖南中医杂志,2018,34(7):228-231.
|
[12] |
李娟,张龙,雷春龙,等. 黄芪黄酮的研究进展[J]. 畜牧与饲料科学,2019,40(3):65-67.
|
[13] |
于玲,王知斌,王秋红,等. 黄芪中黄酮类化合物药理作用研究进展[J]. 中医药信息,2018,35(2):104-108.
|
[14] |
叶飞. 黄芪总皂苷提取方法研究进展探析[J]. 中国石油和化工标准与质量,2017,37(18):100-101.
|
[15] |
张蔷,高文远,满淑丽. 黄芪中有效成分药理活性的研究进展[J]. 中国中药杂志,2012,37(21):3203-3207.
|
[16] |
梅周芳,施天昀,都勇,等. 黄芪甲苷研究进展[J]. 临床医药文献电子杂志,2017,4(3):586-587.
|
[17] |
唐冕,许晓芬. 药用黄芪皂苷类化学成分及药理作用研究进展[J]. 中医药导报,2018,24(20):117-122.
|
[18] |
王玲丽,丰华玲,杨柯,等. 黄芪生物学及化学成分研究进展[J]. 基因组学与应用生物学,2017,36(6):2581-2585.
|
[19] |
孙政华,邵晶,郭玫. 黄芪化学成分及药理作用研究进展[J]. 中医临床研究,2015,7(25):22-25.
|
[20] |
王培昌,张建,张宗玉,等. 黄芪碱化合物HDTIC-1和2对衰老相关基因p16和p21表达的影响[J]. 首都医科大学学报,2007,28(2):145-149.
|
[21] |
MAIER R,KREBS P,LUDEWIG B.Immunopathological basis of virus-induced myocarditis[J]. Clin Dev Immunol,2004,11(1):1-5.
|
[22] |
ZHU H Y, ZHANG Y Y, YE G, et al.In vivo and in vitro antiviral activities of calycosin-7-O-β-D-glucopyranoside against coxsackie virus B3[J]. Biol Pharm Bull,2009,32(1):68-73.
|
[23] |
蔡文吉. 黄芪中黄酮类成分的抗病毒作用研究[D]. 济南:山东中医药大学,2017.
|
[24] |
梅周芳,陈家君,施天昀,等. 黄芪甲苷对甲型H1N1流感病毒和呼吸道合胞病毒的抑制作用[J]. 中国动物传染病学报,2017,25(5):5-10.
|
[25] |
周红霞. 黄芪甲苷抗甲型流感病毒作用研究[D]. 广州:华南农业大学,2016.
|
[26] |
LIU T, YANG F, LIU J, et al.Astragaloside IV reduces cardiomyocyte apoptosis in a murine model of coxsackievirus B3-induced viral myocarditis[J]. Exp Anim,2019,68(4):549-558.
|
[27] |
ZHANG Y, ZHU H, HUANG C, et al.Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-gamma[J]. J Cardiovasc Pharmacol,2006,47(2):190-195.
|
[28] |
张娟,陈建宗,张金平,等. 黄芪甲甙体外抗乙型肝炎病毒的作用[J]. 第四军医大学学报,2007,28(24):2291-2293.
|
[29] |
WANG S, LI J, HUANG H, et al.Anti-hepatitis B virus activities of astragaloside IV isolated from Radix astragali[J]. Biol Pharm Bull,2009,32(1):132-135.
|
[30] |
MATSUSHIMA Y, SHIMIZU H, KANO A, et al.Novel human adenovirus strain, Bangladesh[J]. Emerg Infect Dis,2012,18(5):846-848.
|
[31] |
商蕾,曲章义,宁莉莉,等. 黄芪甲苷体外抗腺病毒作用研究[J]. 中国药理学通报,2013,29(6):854-858.
|
[32] |
SHANG L, QU Z, SUN L, et al.Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro[J]. J Pharm Pharmacol,2011,63(5):688-694.
|
[33] |
郑兰兵,魏青,刘小玲,等. 黄芪多糖体外抗CVB3病毒活性[J]. 中国医药指南,2011,9(13):45-47.
|
[34] |
邹宇宏,杨雁,吴强,等. 黄芪提取物的体外抗乙肝病毒作用[J]. 安徽医科大学学报,2003,38(4):267-269.
|
[35] |
DANG S S, JIA X L, SONG P, et al.Inhibitory effect of emodin and Astragalus polysaccharide on the replication of HBV[J]. World J Gastroenterol,2009,15(45):5669-5673.
|
[36] |
GABLE J E, ACKER T M, CRAIK C S.Current and potential treatments for ubiquitous but neglected herpesvirus infections[J]. Chem Rev,2014,114(22):11382-11412.
|
[37] |
SHI L H, YIN F L, XIN X G, et al.Astragalus polysaccharide protects astrocytes from being infected by HSV-1 through TLR3/NF-KAPB signaling pathway[J]. Evid Based Complement Alternat Med,2014,2014:285356.
|
[38] |
GUO Q, SUN X, ZHANG Z, et al.The effect of Astragalus polysaccharide on the Epstein-Barr virus lytic cycle[J]. Acta Virol,2014,58(1):76-80.
|
[39] |
RODRIGUEZ-CARINO C, SEGALES J.Ultrastructural findings in lymph nodes from pigs suffering from naturally occurring postweaning multisystemic wasting syndrome[J]. Vet Pathol,2009,46(4):729-735.
|
[40] |
XUE H, GAN F, ZHANG Z, et al.Astragalus polysaccharides inhibits PCV2 replication by inhibiting oxidative stress and blocking NF-kappaB pathway[J]. Int J Biol Macromol,2015,81:22-30.
|
[41] |
XUE H, GAN F, QIAN G, et al.Astragalus polysaccharides attenuate PCV2 infection by inhibiting endoplasmic reticulum stress in vivo and in vitro[J]. Sci Rep,2017,7:40440.
|
[42] |
SONG M Y, CHEN Y, DU H X, et al.Raw rehmannia radix polysaccharide can effectively release peroxidative injury induced by duck hepatitis A virus[J]. Afr J Tradit Complement Altern Med,2017,14(4):8-21.
|
[43] |
WANG Y, CHEN Y, DU H, et al.Comparison of the anti-duck hepatitis A virus activities of phosphorylated and sulfated Astragalus polysaccharides[J]. Exp Biol Med (Maywood), 2017, 242(3):344-353.
|
[44] |
CHEN Y, SONG M, WANG Y, et al.The anti-DHAV activities of Astragalus polysaccharide and its sulfate compared with those of BSRPS and its sulfate[J]. Carbohydr Polym,2015,117:339-345.
|
[45] |
ZHANG P, LIU X, LIU H, et al.Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication[J]. Microb Pathog,2018,114:124-128.
|
[46] |
KALLON S, LI X, JI J, et al.Astragalus polysaccharide enhances immunity and inhibits H9N2 avian influenza virus in vitro and in vivo[J]. J Anim Sci Biotechnol,2013,4(1):22.
|
[47] |
熊敏,张荫杰,徐世军. 黄芪抗病毒作用研究进展[J]. 中药与临床,2012,3(4):50-53.
|
[48] |
李娜,李峰. 黄芪抗病毒作用研究进展[J]. 山东中医杂志,2015,34(7):566-568.
|
[49] |
倪力强,陶弘武,杨小林,等. 中药预防新型冠状病毒肺炎策略与分析[J/OL].中华中医药学刊,http://kns.cnki.net/kcms/detail/21.1546.r.20200305.0914.002.html,2020-04-17.
|
[50] |
陈莉莉,葛广波,荣艳,等. 中药在新冠肺炎防治中的应用和研究进展[J]. 上海中医药大学学报,2020,34(3):1-8.
|